# Contrast Enhanced Ultrasound in COVID-19

> **NCT04640038** · PHASE3 · COMPLETED · sponsor: **Children's Hospital of Philadelphia** · enrollment: 4 (actual)

## Conditions studied

- Covid19
- Multisystem Inflammatory Syndrome in Children (MIS-C)

## Interventions

- **DRUG:** Sulfur hexafluoride lipid-type A microspheres

## Key facts

- **NCT ID:** NCT04640038
- **Lead sponsor:** Children's Hospital of Philadelphia
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-18
- **Primary completion:** 2021-09-17
- **Final completion:** 2021-09-17
- **Target enrollment:** 4 (ACTUAL)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04640038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04640038, "Contrast Enhanced Ultrasound in COVID-19". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04640038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*